Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT00343213
Other study ID # 3454
Secondary ID
Status Recruiting
Phase N/A
First received June 21, 2006
Last updated August 29, 2011
Start date June 2006

Study information

Verified date August 2011
Source University Hospital, Strasbourg, France
Contact Jean-Jacques Baldauf, MD
Phone 3.33.88.12.74.59
Email jean-jacques.baldauf@chru-strasbourg.fr
Is FDA regulated No
Health authority France: Ministry of Health
Study type Interventional

Clinical Trial Summary

P16INK4a has recently been described as a surrogate marker for HR-HPV associated squamous and glandular intraepithelial lesions of the cervix. The immunohistochemical staining pattern of p16INK4a in high grade intraepithelial neoplasia of the cervix (CIN 2 and 3) is diffuse, whereas in CIN 1 different staining patterns (diffuse, sporadic, focal or negative) can be seen. The aim of our study is to find out whether the p16INK4a staining pattern of CIN 1 is able to predict the outcome of the lesion. The retrospective part of the study includes cervical biopsies of 200 patients with CIN 1 and clinical follow-up for at least 5 years. p16INK4a staining and HPV detection by IHC will be correlated to clinical outcome.The prospective part of the study includes 300 patients with CIN 1 and LSIL on cytology. HPV detection by HCII and p16INK4a immunohistochemistry on liquid based cytology samples as well as p16INK4a staining and HPV detection by ISH on colposcopy guided biopsies will be correlated to clinical follow-up and colposcopy findings. Slides are analysed by 2 pathologists without knowledge of clinical data.


Recruitment information / eligibility

Status Recruiting
Enrollment 300
Est. completion date
Est. primary completion date
Accepts healthy volunteers No
Gender Female
Age group 18 Years and older
Eligibility Responsible women > 18 years with histologically proven CIN 1

Study Design

Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double-Blind, Primary Purpose: Prevention


Intervention

Procedure:
colposcopy


Locations

Country Name City State
France Service de Gynécologie-Obstétrique - Centre Hospitalier Général Haguenau
France Service de gynécologie-obtétrique - Centre Hospitalier Général Saverne
France Département de Gynécologie-Obstétrique - Hôpital de Hautepierre Strasbourg

Sponsors (1)

Lead Sponsor Collaborator
University Hospital, Strasbourg, France

Country where clinical trial is conducted

France, 

Outcome

Type Measure Description Time frame Safety issue
Primary p16INK4a staining pattern and HPV status of the initial biopsy
Secondary p16INK4a staining pattern and histologic diagnosis of follow-up biopsies correlated with colposcopic findings.